INT16088

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1991
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 7
Disease Relevance 0.29
Pain Relevance 0.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Ltc4s) nuclear envelope (Ltc4s) lyase activity (Ltc4s)
endoplasmic reticulum (Ltc4s) nucleus (Ltc4s)
Anatomy Link Frequency
BMMC 4
macrophages 2
Ltc4s (Mus musculus)
Pain Link Frequency Relevance Heat
diclofenac 5 98.50 Very High Very High Very High
Inflammation 1 98.24 Very High Very High Very High
Arthritis 1 95.68 Very High Very High Very High
Analgesic 1 90.96 High High
cINOD 6 83.84 Quite High
COX2 6 25.00 Low Low
Pain 1 25.00 Low Low
Disease Link Frequency Relevance Heat
INFLAMMATION 7 98.24 Very High Very High Very High
Experimental Arthritis 1 96.40 Very High Very High Very High
Pressure And Volume Under Development 1 92.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
All five metabolites were more than 50 times less potent than diclofenac in inhibiting PGE2 production in zymosan-stimulated mouse macrophages and LTC4 synthesis was not inhibited in these cells.
Negative_regulation (inhibited) of Gene_expression (synthesis) of LTC4 in macrophages associated with diclofenac
1) Confidence 0.58 Published 1991 Journal Agents Actions Section Abstract Doc Link 1793018 Disease Relevance 0.29 Pain Relevance 0.40
Furthermore, this compound consistently inhibited the production of leukotriene C4 (LTC4), as well as the degranulation reaction in BMMC, with an IC50 value of 5.7 microM and 9 microM, respectively, and these effects occurred in a dose dependent fashion.
Negative_regulation (inhibited) of Gene_expression (production) of leukotriene C4 in BMMC
2) Confidence 0.35 Published 2008 Journal Arch. Pharm. Res. Section Abstract Doc Link 18365692 Disease Relevance 0 Pain Relevance 0.07
In addition, this compound consistently inhibited the production of leukotriene C4 (LTC4) in a dose dependent manner, with an IC50 value of 6.56 microM.
Negative_regulation (inhibited) of Gene_expression (production) of LTC4
3) Confidence 0.33 Published 2006 Journal Arch. Pharm. Res. Section Abstract Doc Link 16681032 Disease Relevance 0 Pain Relevance 0.07
Furthermore, this compound consistently inhibited the production of leukotriene C4 (LTC4), as well as the degranulation reaction in BMMC, with an IC50 value of 5.7 microM and 9 microM, respectively, and these effects occurred in a dose dependent fashion.
Negative_regulation (inhibited) of Gene_expression (production) of LTC4 in BMMC
4) Confidence 0.25 Published 2008 Journal Arch. Pharm. Res. Section Abstract Doc Link 18365692 Disease Relevance 0 Pain Relevance 0.07
In addition, this compound consistently inhibited the production of leukotriene C4 (LTC4) in a dose dependent manner, with an IC50 value of 6.56 microM.
Negative_regulation (inhibited) of Gene_expression (production) of leukotriene C4
5) Confidence 0.24 Published 2006 Journal Arch. Pharm. Res. Section Abstract Doc Link 16681032 Disease Relevance 0 Pain Relevance 0.07
Furthermore, MG consistently inhibited the production of leukotriene C4 (LTC4) in a dose dependent manner, with an IC50 value of 5.3 microM.
Negative_regulation (inhibited) of Gene_expression (production) of LTC4
6) Confidence 0.11 Published 2006 Journal Arch. Pharm. Res. Section Abstract Doc Link 17121182 Disease Relevance 0 Pain Relevance 0.08
Furthermore, MG consistently inhibited the production of leukotriene C4 (LTC4) in a dose dependent manner, with an IC50 value of 5.3 microM.
Negative_regulation (inhibited) of Gene_expression (production) of leukotriene C4
7) Confidence 0.08 Published 2006 Journal Arch. Pharm. Res. Section Abstract Doc Link 17121182 Disease Relevance 0 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox